Pharma Services

Accelerating diagnostic and therapeutic research to improve patients’ lives

Providing access to expertise, manufacturing, products and services to enable precisely targeted trials

GE Healthcare Pharma Services

Working towards a better future for patients

Chronic illnesses destroy lives of both sufferers and caregivers. Despite pioneering research to create disease modifying therapeutics in neurology, cardiology and oncology care areas, there are still significant advancements yet to be made to help patients overcome these complex diseases. Such diseases are not only a destructive force to patients but additionally to their loved ones. By 2030, there will be a projected 82 million people living with dementia1. Cardiovascular diseases represent up to 31% of all global deaths, with more people dying annually than any other cause2. By 2040, there will be 27.5 million new cases of cancer each year3.

Pharma Services at a Glance

  • 10,000+
    Doses delivered for clinical trials  worldwide since 2012

  • 30+
    Products across care areas and modalities

  • 98%
    Success for global imaging agent deliveries*


  • 200+
    Clinical studies within
    10 years

  • 450+
    Imaging sites supplied to in total


  • 30+
    Countries supported for dose supply

  • 10
    Functions streamlined



  • 1
    Single Point of Contact


*2019, global SPECT
4 Pillars

  • Enabling Accurate Patient Selection

    Using imaging tracers as diagnostic tools in patient selection and therefore ensure the right patients are selected for your cohort. This approach to patient selection can demonstrate savings and eliminate non responders from the cohort that do not have a specific pathology helping to demonstrate maximum efficacy. Application of imaging agents as part of a clinical trial methodology can be conducted as needed; only at initial patient selection or longitudinal usage to monitor disease progression.

  • Confidence in Patient Scheduling

    Knowing that a partner can be relied upon to support screening readiness is essential. Through a robust supply chain with a 98%* delivery success rate, we work round the clock to give you confidence in patient scheduling within your studies. GE Healthcare has supported efficient and timely execution of over 200 studies, ensuring on-time study results and reduced patient wait times.

    *2019, SPECT

  • Consistent Results When Scaling

    To provide flexibility as needed and consistent results when scaling, GE Healthcare offers an established global network of clinical partners with a footprint of over 450 imaging sites and supply channels across over 30 countries. This network and production capability provides access to major metropolitan areas around the world for PET and SPECT tracer supply and other imaging solutions. 

    This allows the flexibility to accommodate the geographical needs of a project and to explore options for supply into new regions. 

  • Simplified Study Management Powered by Collaboration

    Flexibility in commercial services in critical set-up and lifecycle management processes increase productivity and can mitigate patient data risks. GE Healthcare provides a single point of contact across several functional stakeholders providing a simplified, seamless and integrated end-to-end service to manage study dose supply across the globe. This service model includes streamlined contracting, centralized billing/invoicing and project tracking through regular meetings.

Partnering with you across all care areas

Neurology

Oncology

Cardiology

Digital

Contact Us

JB00799AFG